Original research by Periodontics Emine et al.
Original research
Periodontics
Emine PIRIM GORGUN(a) 
Hulya TOKER(a) 
Ertan Mahir KORKMAZ(b) 
Omer POYRAZ(c)
 (a) Cumhuriyet University Faculty of Dentistry, 
Department of Periodontology, Sivas, Turkey.
 (b) Cumhuriyet University Faculty of Sciences, 
Department of Molecular Biology and 
Genetics, Sivas, Turkey. 
 (c) Cumhuriyet University Faculty of Medicine, 
Department of Microbiology, Sivas, Turkey.
IL-6 and IL-10 gene polymorphisms in 
patients with aggressive periodontitis: 
effects on GCF, serum and clinic 
parameters 
Abstract: Genetic variations observed in cytokines affect periodontitis 
susceptibility. The aim of this study was to investigate interleukin(IL)-6(-174) 
and IL-10(-597) gene polymorphisms in generalized aggressive periodontitis 
(GAgP) patients. Also, we aimed to evaluate the effects of IL-6 and 
IL-10 gene polymorphisms on the clinical outcomes of non-surgical 
periodontal therapy and cytokine levels in gingival crevicular fluid(GCF) 
and serum. Fifty-three patients with GAgP and 50 periodontally healthy 
individuals were included in this study. Clinical parameters, GCF and 
blood samples were collected at baseline and at 6-week. Non-surgical 
periodontal therapy was performed in patients with GAgP. Gene analysis 
were determined by PCR-RFLP(polymerase chain reaction-restriction 
fragment length polymorphism) and cytokine levels were determined 
by enzyme-linked immunosorbent assay(ELISA).GAgP patients showed 
significant improvement on clinical parameters after periodontal 
therapy(p<0.05). In the GAgP group, IL-6 GG genotype and G allele 
frequency were higher than in the control group. GCF IL-6 level was 
also significantly lower at 6-week in the GAgP group. Higher GCF IL-10 
levelswere observed in patients carrying the IL-6 GG genotype than in 
those carrying the GC+CC genotype at baseline. In conclusion, IL-6(-174) 
and IL-10(-597) gene polymorphisms were found to be associated 
with GAgP and genotype distribution did not affect the outcome of 
non-surgical periodontal therapy, while patients with IL-6(-174) GG 
genotype had higher levels of GCF IL-10 levels.
Keywords: Interleukin-6; Interleukin-10; Polymorphism, Genetic; 
Aggressive Periodontitis.
Introduction
Aggressive periodontitis (AgP) is a rapidly progressing form of 
periodontal disease. Specific microbial environment and modified host 
response play crucial roles in the development and progression of the 
disease.1 AgP patients display inadequate host response to increased 
expression of a variety of immunological and genetic risk factors.2 The 
genetic risk of AgP development has been investigated in many studies 
in various populations.3,4,5
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There is a complex network of pro- and 
anti-inflammatory cytokines acting in the diseased 
periodontal tissues.6,7 Also, cytokine expressions 
are affected by the presence of funct ional 
gene polymorphisms.6
Interleukin (IL)-6 is a pleiotropic cytokine released 
by many cell types, and its secretion levels are 
determined by the producing cell type and the 
genetic background of the source cells.8 Among 
several kinds of cytokines, IL-6 was found to be 
increased in gingival crevicular fluid (GCF) and 
gingival tissues of patients with periodontal disease.9 
A  recent study reported that chronic periodontitis(CP) 
and generalized aggressive periodontitis (GAgP) 
patients had significantly higher GCF IL-6 levels in 
comparison with the healthy subjects.10
Single nucleotide polymorphisms(SNPs) in the 
promoter region of IL-6 gene at positions -174G/C(rs 
1800795), -572C/G(rs 1800796) and -597G/A(rs 
1800797) have been described. First, Trevilatto et al. 
reported an association between IL-6(-174) gene 
polymorphism and CP in the Caucasian race.11 After 
that,several studies found different results regarding 
the relationship between IL-6(-174) gene polymorphism 
and periodontal disease. Some of these studies did 
not find any association between IL-6(-174) gene 
polymorphism and CP,12,13,14,15 however some others 
found associations.16, 17
Studies investigating the relationship between 
IL-6(-174) gene polymorphism and AgP are 
limited.3,5,18,19,20 Erciyas et al.20 evaluated the IL-6(-174) 
single nucleotide polymorphisms (SNPs) in AgP 
in Turkish populationand found no association. 
However, Nibali et al.5 reported an association 
between IL-6(-174)GG genotype and AgP, and another 
study showed an association between IL-6(-174)GC 
genotype and AgP.18
IL-10, an anti-inflammatory cytokine, regulates 
the synthesis of pro-inflammatory cytokines such 
as IL-1, -2, -6 and stimulates protective antibody 
production.6,21 IL-10 is expressed in both healthy 
and diseased human periodontal tissues and is 
reported to be reduced in patients infected with 
Aggregatibacter actinomycetemcomitans.22
The gene encoding IL-10 was mapped to 
chromosome 1q31-32. The three SNPs(-1082 G/A; -819 
C/T and -592 C/A) from the transcriptional start site 
have been associated with the altered synthesis of 
IL-10 in response to inflammatory stimuli.23 In the 
literature, data on which of the IL-10 polymorphisms 
or variations contributes to periodontal disease are 
contradictory.4,21,24 The IL-10 gene polymorphism 
at position -597 C to A wasnot associated with the 
susceptibility to CP or AgP.4
Considering the key roles of pro-inflammatory 
and anti-inflammatory cytokines in periodontal 
disease, it was quest ioned whether genet ic 
variations affecting transcription or function of 
these cytokines contribute to the development 
of GAgP. Also, few studies have investigated the 
potential association of carrying a gene variant with 
the clinical response to periodontal therapy. The 
present study was undertaken to test the hypothesis 
that gene polymorphisms may affect periodontal 
inflammation and treatment outcomes via pro- and 
anti-inflammatory cytokine levels in AGP patients. 
Thus,the aims of this study were separated in three 
parts: first,to determine IL-6(-174) and IL-10(-597) 
gene polymorphisms in GAgP patients and healthy 
controls;second, to evaluate the effect of these 
gene polymorphisms on outcomes of non-surgical 
periodontal therapy; and third to investigate the 
effect of genotype distributions on cytokine levels 
in GCF and serum.  
Methodology
Study population
Fifty-five patients with GAgP and 50 periodontally 
and systemically healthy individuals were recruited 
from the Department of Periodontology at Cumhuriyet 
University from 2011 to 2013. The study protocol was 
approved by the Medical Research Ethics Committee 
of Cumhuriyet University according to the Helsinki 
declarations (2011/031), and signed informed consent 
was obtained from all individuals.
Individuals who were evaluated for the present 
study were excluded if they had conservative 
or prosthetic restorations at the anterior region, 
presence of systemic disease, history of hepatitis or 
HIV infection, immunosuppressive chemotherapy 
or current pregnancy or lactation, requirement 
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for antibiotic prophylaxis, history of antibiotic 
therapy in the previous 3 months, chronic usage of 
anti-inflammatory drugs and periodontal treatment in 
the previous 6 months. Also, smokers were excluded 
from the study.
The diagnostic criteria for GAgP was defined in 
accordance with the classification developedby the 
American Academy of Periodontology.1 Patients who 
presented with a generalized severe periodontal 
destruction (probing depth ≥ 5mm at least on 
three sites other than first molars and incisors, and 
radiographic evidence of advanced alveolar bone 
loss) were diagnosed with GAgP.
Control subjects were designated as healthy if they 
had full-mouth probing pocket depth (PD) < 3mm, 
gingival index scores equal to 0, andno radiographic 
evidence of alveolar bone loss. These individuals were 
included in the study as systemically and periodontally 
healthy volunteers. Also, all individuals came from 
the same geographical area.
Clinical measurements and periodontal 
therapy
Before crevicular fluid collection, full-mouth 
clinical periodontal measurements were recorded 
at six sites per tooth(mesio-buccal, mid-buccal, 
disto-buccal, disto-lingual, mid-lingual and 
mesio-lingual), including plaque index(PI),25 gingival 
index(GI),25 PD and clinical attachment level (CAL). 
A periodontal probe (Williams probe, Hu-Friedy, 
Chicago, IL, USA) was used for periodontal 
measurements. In all patients, individual acrylic 
stents were fabricated with grooves as reference 
points for CAL measurement. The periodontal 
status of each patient was determined by a single 
calibrated researche (E.P.G.), who had experience 
in clinical trials. In patients with GagP, clinical 
periodontal measurements were performed at 
baseline and at 6-week. GAgP subjects received 
non-surgical periodontal therapy, which consists 
of oral hygiene instructions, scaling and root 
planning. The treatment procedure was performed 
quadrant per quadrant under local anesthesia 
in four visits using specific curettes (Hu-Friedy, 
Chicago, IL, USA). Treatment was completed within 
10 days. No antibiotics were prescribed during the 
treatment. All patients were treated by a single 
periodontist (E.P.G.). 
GCF and serum sampling
GCF sampling was carried out during the same 
session as the clinical measurements.Only the 
upper anterior teeth were included in the study to 
facilitate the access and to reduce the risk of salivary 
contamination during the procedures.GCF samples 
were collected from a proximal site of a single-rooted 
tooth with moderate pocket size in GagP patients 
and one site in control group.The GCF samples were 
collected using an absorbent paper strip(Periopaper; 
ProFlow Inc., Amityville, NY, USA), which was 
placed into the sulcus/pocket until mild resistance 
was felt and then held there for 30s.26 The procedure 
was performed carefully to avoid mechanical injury. 
Strips with contamination of blood were excluded. All 
strips with GCF were immediately and individually 
placed into sterile Eppendorf tubes and kept at -80ºC 
until required for further analysis.
Blood samples (5 ml) were taken from the 
antecubital vein of all individuals and collected in 
tubes.Venous blood sampleswere allowed to stand 
for 30min before being centrifuged at 6000rpm for 
10min. All samples were kept in -80ºC conditions 
until the day of analysis.
Cytokine assay
On the day of the assay, 100 µl phosphate buffer 
solution was added to GCF samples in Eppendorf 
tubes. GCF samples were mixed with a vortex for 
1min to mix the solution. After removal of the strips, 
the supernatants were divided into two aliquots for 
the determination of each cytokine. The amounts of 
IL-6 and IL-10 in the serum and GCF were determined 
by using ELISA kits (Invitrogen, Cambrillo,USA) 
according to manufacturer’s instructions. After 
color development was stopped, the absorbance was 
measured using a microtiter plate-computerized reader 
set to a wavelength of 450nm. GCF cytokine levels 
were calculated from the standard curves and defined 
as picogram/site for total amount of cytokine levels. 
The sensitivities for IL-6 and IL-10 ELISA’s were 2 and 
1 pg/mL, respectively. Sites with cytokine levels below 
the limits of the assay’s detectability were scored as 0.
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Genotype analyses
Two mL of blood was taken from each individual at 
baseline. The blood samples were collected in sodium 
EDTA vacutainers and stored at –80°C until genetic 
analysis were performed. The extraction of DNA was 
performed with a commercial kit(Invitrogen, Cambrillo, 
USA) following the manufacturer’s protocol.  
Each sample of  DNA was analyzed for 
polymorphisms in the IL-6 gene at position -174, and 
in the IL-10 gene at position -597 with PCR-RFLP. Primer 
sequences are shown for each primer pair in Table 1.
DNA samples were amplified by PCR (PTC-200 
termal cycler, MJ Research, Watertown, MA, USA) with 
specific primers for each examined polymorphism. 
PCR reaction mixtures (50 µl) contained 50 µl PCR 
buffer, 0.2 mM each dNTP, 10 pmol of each primer 
(forward and reverse, control and allele specific), 
1.5 m MMgCl2, 200 ng of genomic DNA, 0.5U Taq 
DNA polymerase (Fermantes,Maryland, USA) and 
each internal control primer.  
For IL-6(-174) G/C, the following PCR protocol 
was used: 94°C for 3 min (initial denaturation), 94°C 
for 30s (denaturation), 62.6°C for 40s (annealing), and 
72°C for 40s (extension). The total number of cycles 
was 35 followed by a final extension of 72°C for 5min. 
We used NlaIII and a cleavage protocol following 
the manufacturer’s instructions. NlaIII cleaves a 
restriction site at position -174 when G is present, 
leading to fragments of 29, 176, 202, and 233 base 
pairs (bp) in length or 29, 111, 122, 176 and 202 bp 
when C is present. In heterozygote individuals (A/C), 
fragments have 42, 66, 232, 240 and 306 bp in length. 
For IL-10 (-597)A/C, the following PCR protocol 
was used: 94°C for 3min (initial denaturation), 94°C 
for 30s (denaturation), 48°C for 40s (annealing), and 
72°C for 40s (extension). The total number of cycles 
was 35 followed by a final extension of 72°C for 5 min. 
We used RsaI and a cleavage protocol following the 
manufacturer’s instructions. RsaI cleaves a restriction 
site at position -597 when A is present, leading to 
fragments of 42, 66, 232, and 240 bp in length or 42, 
232, and 306 bp when C is present. In heterozygote 
individuals fragments have (A/C), 42, 66, 232, 240 
and 306 bp in length.
The alleles were separated by 3% agarose gel 
electrophoresis and stained with ethidium bromide. 
Following electrophoresis, the PCR products were 
visualized under ultraviolet light. 
Statistical analysis
The chi-square test was used to test for deviation 
of genotype frequencies from Hardy- Weinberg 
equilibrium and to compare the genotype distributions 
among individuals with GAgP and healthy controls. 
Odds ratios (ORs) and 95% confidence intervals were 
calculated to determine the strength of the association. 
A p-value of < 0.05 was considered significant. 
Statistical analyses were performed using the 
program SPSS 15.0 (SPSS Inc., Chicago, IL, USA). 
Demographic data and clinical parameters were reported 
as means± standard deviation. Genotype frequencies 
were tabulated by direct counting and allele frequencies 
were calculated from the observed number of genotypes. 
Kolmogorov-Smirnov test was used to assess the 
distribution of data. Comparisons among groups were 
performed using the Mann-Whitney U test. In the GAgP 
group, differences between baseline and 6-week values 
were analyzed by Wilcoxon rank test.  The relationships 
among GAgP group and gene polymorphisms were 
analyzed by logistic regression analysis. The power 
of the analysis was defined by utilizing data from a 
previous publication.21 The sample size was calculated 
under a 5% error giving a required sample size of 55 in 
each group, with a statistical power of 80%.
Table 1. Primer sequences and reaction properties for genes. 









tA: Annealing temperature; bp: base pairs of amplicon size.
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Results
Clinical findings
Two of the GAgP patients did not complete the 
periodontal therapy and were excluded from the 
study. The mean age and sex distribution showed no 
difference between the groups (p > 0.05) (Table 2). 
In theGAgP group, all clinical parameters at 6-week 
were significantly lower than in baseline (p < 0.05) 
(Table 3). Also, there was no significant difference 
between the GAgP and healthy control groups 
regarding PI, GI and PD values at 6-week. 
Distribution of genotypes and allele 
frequencies
The frequency of IL-10 genotypes in the GAgP 
and healthy control was found in accordance with 
Hardy-Weinberg equilibrium (p > 0.05), whereas IL-6 
genotypes showed disequilibrium (p <0.05).
IL-6 (-174) G/C and IL-10 (-597) A/C genotype 
distributions were significantly different between 
groups (p = 0.007, p = 0.006, respectively) (Table 4). 
In the GAgP group, IL-6 GG genotype was associated 
with 2.1 times higher risk of GAgP compared to 
IL-6 GC/CC genotype, however, this risk was not 
statistically significant (OR:2.1, 95%Cl: 0.96–4.64, 
p > 0.05). Conversely, IL-10 AA genotype was 
significantly associated with 7 times higher risk of 
GAgP compared to IL-10 AC/CC genotype (OR:7, 
95%Cl: 1.48–33.22, p < 0.05). 
Considering allele frequencies in both groups, 
IL-10 A allele frequency was similar in the GAgP 
and healthy control (p > 0.05). However there was a 
significant difference between the study groups in 
IL-6 G allele frequency. The frequency of G allele was 
higher in the GAgP group compared to the healthy 
control group (p < 0.05).
Cytokine levels in GCF and serum
In GAgP group, GCF IL-6 levels were significantly 
decreased after periodontal treatment (p < 0.05, 
Table 5). Also in GAgP group, GCF IL-6 cytokine 
levels at baseline and 6-week were significantly 
higher compared to the control group (p < 0.05). 
After periodontal treatment, serum IL-6 levels were 
decreased, but not significantly.
GCF and serum IL-10 levels at 6-week were higher 
than those of baseline, but these differences were not 
statistically significant in the GAgP group. 
In the GAgP group, individuals were categorized 
according to the IL-6 and IL-10 genotype distribution, 
and then changes in clinical and biochemical 
parameters were evaluated (Table 6).Significant 
improvements in clinical parameters were found 
after non-surgical periodontal therapy in individuals 
with both IL-6 and IL-10 genotypes (p < 0.05). 
In bivariate comparisons, higher PD values were 
foundin patients carrying IL-6 GG genotype than the 
IL-6 GC+CC genotypeat baseline (p < 0.05) and higher 
CAL values were observed in patients carrying the 
IL-6 GG genotype at 6-week (p < 0.05). 
In patients carrying IL-6 GC+CC genotype, there 
was a statistically significant decrease in GCF IL-6 
levels at 6-week. However, in comparisons between 
IL-6 genotypes, serum and GCF IL-6 levels were not 
significantly different at 6-week. At baseline, higher 
Table 2. Demographic characteristic of study groups.
Variable
GAgP Healthy controls
(n = 53) (n = 50)
Age (years)
Mean±SD 29.7 ± 6.2 31.8 ± 5.2
Range 15–44 23–43
Gender
Male n(%) 24(45.3) 17(34)
Female n(%) 29(54.7) 33(66)
GAgP: generalized aggressive periodontitis; SD: standard deviation.
Table 3. Clinical parameters at baseline and 6-week for study 
groups (mean ± SD).
Parameter (mean ±SD) GAgP Healthy controls
PI
Baseline 1.5 ± 0.7b  -
6-week 0.3 ± 0.5a 0.2 ± 0.4
GI
Baseline 2 ± 0.5b - 
6-week 0.6 ± 0.5a 0.1 ± 1.3
PD
Baseline 5.2 ± 0.6b - 
6-week 3.1 ± 1a 2 ± 0.7
CAL
Baseline 8.7 ± 2.5 - 
6-week 6.9 ± 2.6a NA
ap < 0.05 different from baseline; bp < 0.05 different from 
healthy controls; GAgP: generalized aggressive periodontitis; PI: 
plaque index; GI: gingival index; PD: pocket depth; CAL: clinical 
attachment level; NA, not applicable.
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GCF IL-10 levels were found in patients carrying the 
IL-6 GG genotype than in those carrying the IL-6 
GC+CC genotype (p < 0.05).
GCF IL-6 level was a significantly decreased in 
patients carrying the IL-10 AC+CC genotype after 
periodontal treatment. Also, there was no significant 
differences in GCF and serum IL-10 levels after 
non-surgical periodontal therapy in individuals with 
both IL-10 genotypes (p > 0.05).
Finally, we evaluated whether IL-6 and IL-10 
genotype distributions affect the response to non-surgical 
periodontal therapy. Differences in clinical parameters 
were analyzed according to genotype distribution and 
no significant difference was found (Table 7).
In GAgP patients, logistic regression analysis 
was used to evaluate the association of the IL-6 GG 
and IL-10AA genotypes with periodontal disease 
susceptibility, while adjusting for confounders such 
as age and gender. It was found that neither age nor 
gender had effects on genotype diversity.
Discussion
Polymorphisms in the regulatory regions of the 
cytokine genes may change cytokine expression. 
Therefore, the polymorphisms of cytokine genes 
are potentially important as genetic predictors of 
the disease susceptibility and clinical outcomes.27 
In our study, periodontal therapy improved clinical 
results and decreased GCF IL-6 level, consistently 
with the literature.28 Also, in patients with IL-6 
GC+CC and IL-10 AC+CC genotypes, GCF IL-6 level 
was decreased at 6-week. We showed that reduced 
clinical inflammation was related to lower GCF 
IL-6 cytokine level. Contrary to our study, Oliveira 
et al.29 reported that GCF IL-6 level was increased in 
GAgP patients after treatment, but not significantly. 
The authors explained this situation by affirming 
that IL-6 acts both as pro- and anti-inflammatory 
cytokine at the same time. Furthermore, similar to 
our results, Becerik et al.10 demonstrated that in GAgP 
group, GCF IL-6 cytokine level was higher than in 
the control group and plasma levels of IL-1beta and 
IL-6 were similar among GAgP, CP and gingivitis 
patients,and controls. Also, in this study, serum IL-6 
level decreased after non-surgical periodontal therapy, 
but the difference was not significant. Contrary 
to our findings, Shimada et al. and D’Aiuto et al. 
reported that serum IL-6 level was decreased after 
periodontal therapy.28,30 GCF and serum IL-10 levels 
increased after periodontal therapy, but no significant 
difference was detected. Lappin et al.31 suggested 
that the numbers of inflammatory leucocytes that 
express the IL-10 were increased in aggressive 
periodontitis compared to chronic periodontitis, and 
thenumbers of inflammatory leucocytes that express 
Table 4. Distribution of the IL-6 (-174) and IL-10 (-597) 




n = 53 n = 50
Genotypes
IL-6(-174)
CC 4(7.5) 16(32)  -
GC 18(34) 14(28) 0.007*
GG 31(58.5) 20(40)  -
IL-10(-597)
CC 7(13.2) 3(6)  -
AC 34(64.2) 45(90) 0.006*
AA 12(22.6) 2(4)  -
Allele frequencies
IL-6(-174)    -
C 26(24.5) 46(46) 0.001*
G 80(75.5) 54(54)  -
IL-10(-597)    
C 48(45.28) 51(51) 0.274
A 58(54.8) 49(49)  -
*p < 0.05; GAgP: generalized aggressive periodontitis.
Table 5.Gingival crevicular fluid(GCF) and serum IL-6 and 
IL-10 levelsat baseline and 6-week (pg/30s, mean±SD).
Variable GAgP Healthy controls
GCF
IL-6
Baseline 126.1 ± 214.9b - 
6-week 52.9 ± 92.9a,b 21.3 ± 52.3
IL-10
Baseline 5.5 ± 10.7  -
6-week 10.5 ± 23.2 6.9 ± 13.3
Serum
IL-6
Baseline 14.2 ± 30.8  -
6-week 8.8 ± 22.8 3.1 ± 11.4
IL-10
Baseline 4.4 ± 19.4  -
6-week 6.4 ± 24.4 0.8 ± 2.6
ap < 0.05, different from baseline; bp < 0.05, different from 
healthy controls; GAgP: generalized aggressive periodontitis.
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IL-10 are morewidely distributed than the IL-6 and 
TNF-alpha. It was demonstrated that periodontal 
therapy improved GCF cytokine profiles by lowering 
IL-1β and increasing IL-10 levels but the mean change 
in IL-10 did not differ between AgP and control 
groups.29 Similarly, these findings were observed in 
our previous study.7 
In the literature, there are few studies investigating 
the relationship between AgP and IL-6 gene 
polymorphisms.6,20,32,33 Supporting our results, 
Nibali et al.reported that IL-6 GG genotype was 
associated with susceptibility to AgP.5 Similarly, 
ameta-analysis indicated that the IL-6(-174) G allele 
did not modify the risk of CP, but increased the risk 
of AgP.34 However, similar to Erciyas et al.,20 Brett 
et al.18 evaluated IL-6(-174) gene polymorphisms 
in CP, AgP and control groups in Caucasians, and 
they found that association between GG genotype 
Table 6. Clinical Parameters, GCF and serum cytokine levels in generalized aggressive periodontitis group distributed by IL-6 and 
IL-10 genotypes.
Clinical parameters
IL-6 (mean ± SD) IL-10 (mean ± SD)
GG (n = 31) GC + CC (n = 22) AA (n = 12) AC+CC (n = 41)
PI
Baseline 1.6 ± 0.7 1.4 ± 0.7 1.3 ± 0.7 1.6 ± 0.7
6-week 0.4 ± 0.5** 0.1 ± 0.5 0.2 ± 0.4 0.3 ± 0.5
p-value p = 0.001* p = 0.001* p = 0.006* p = 0.001*
GI
Baseline 2 ± 0.5 2.1 ± 0.4 1.8 ± 0.7 2.1 ± 0.4
6-week 0.7 ± 0.5 0.5 ± 0.5 0.5 ± 0.5 0.6 ± 0.6
p-value p = 0.001* p = 0.001* p = 0.005* p = 0.001*
PD(mm)
Baseline 5.4 ± 0.6** 4.9 ± 0.7 4.9 ± 0.6 5.3 ± 0.6
6-week 3.3 ± 1 3 ± 0.9 3 ± 0.7 3.2 ± 1
p-value p = 0.001* p = 0.001* p = 0.004* p = 0.001*
CAL(mm)
Baseline 9.1 ± 2.8 8.1 ± 2.1 8.1 ± 2.7 8.9 ± 2.5
6-week 7.5 ± 2.7** 6.1 ± 2.2 6.1 ± 2.5 7.2 ± 2.6
p-value p = 0.001* p = 0.001* p = 0.003* p = 0.001*
GCF IL-6
Baseline 124.3 ± 209.1 128.6 ± 227.8 209.7 ± 335.6 101.6 ± 162.4
6-week 39.6 ± 55.3 71.6 ± 128.0 65.9 ± 121.4 49.1 ± 84.3
p-value p = 0.136 p = 0.017* p = 0.131 P = 0.013*
GCF IL-10
Baseline 8 ± 13** 2.1 ± 4.7 6.6 ± 9.4 5.2 ± 11.1
6-week 9 ± 19.5 12.5 ± 28.1 16.1 ± 26.4 8.8 ± 22.3
p-value p = 0.291 p = 0.171 p = 0.594 p = 0.746
SERUM IL-10 
Baseline 4.5 ± 22.5 9.2 ± 27.2 7.1 ± 24.5 9.7 ± 41.6
6-week 0.5 ± 3 10 ± 29.4 8.3 ± 29 6.9 ± 39
p-value p = 0.655 p = 0.500 p = 0.317 p = 0.866
SERUM IL-6 
Baseline 27.7 ± 91.5 38.3 ± 116.5 34.1 ± 43.8 8.4 ± 23.5
6-week 7.2 ± 16.9 36 ± 116.4 17.5 ± 32.8 6.2 ± 18.7
p-value p = 0.051 p = 0.893 p = 0.068 p = 0.575
*p < 0.05 different from baseline; **p < 0.05 different from IL-6 GC+CC; PI: plaque index; GI: gingival index; PD: pocket depth; CAL: clinical 
attachment level; GCF: gingival crevicular fluid. 
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prevalence was higher in CP/AgP patients compared 
to control, but no association between IL-6 GG 
genotype and AgP was detected. IL-6(-174)G/C and 
(-572)G/C polymorphisms are important regulators 
of transcription and have been shown to affect IL-6 
production. Patients with juvenile rheumatoid arthritis 
carrying the GG genotype have been observed to have 
twice as high IL-6 serum levels as patients with the CC 
genotype.35  Moreover, the IL-6(-174) polymorphism 
was associated with increased odds of the concomitant 
detection of Aggregatibacter actinomycetemcomitans and 
P. gingivalis.3 In contrast, D’Aiuto et al.28 observed that 
in patients with severe periodontal disease, higher 
serum IL-6 levels were associated with the carriage 
of allele C for the IL-6(-174) polymorphism. Terry et 
al.36 reported that genetic polymorphism in the IL-6 
promoter region influence IL-6 gene transcription 
by rather complex interactions determined by the 
haplotype. Also, in a recent report, it was suggested 
that detecting IL-6 haplotype-positive periodontitis 
patients might become helpful in identifying subjects 
who are prone to excessive inflammatory response. 
However, in this study, one SNP of IL-6 gene was 
assessed and we could not find any differences in 
GCF and serum IL-6 levels between GG and GC+CC 
genotypes, but GCF IL-6 levels were decreased in 
patients with the IL-6 GC+CC and IL-10 AC+CC 
genotypes compared with the IL-6 GG patients 
after periodontal treatment. These findings partially 
support that GG genotypes affectIL-6 production in 
GCF but not its serum level.
Although there are limited studies about AgP in 
the literature, different results for IL-10(-592) gene 
polymorphism were demonstrated. Racial and ethnic 
characteristics play a role on these results. Gonzales et al.4 
searched gene polymorphism in IL-10(-592) loci in AgP 
and CP Caucasian patients. Contrary to our results, they 
found no association between IL-10 AA genotype and 
AgP; similar results were found by Hu et al.23 in Chinese 
population. Likewise, A allele in position -592 is 
more frequent in the Chinese population than in a 
Caucasian subgroup.23 In a Jordanian population, the 
frequencies of the IL-10(-1087)A and (-592)A alleles 
were significantly more common in CP patients but 
there was no difference for genotype distribution 
between localize AgP group and controls.37 A recent 
large-scale replication study also suggested that only 
IL-10SNP(rs 61815643) was associated with Dutch and 
German/Austrian AgP samples.38 Claudino et al.39 
studied the effect of IL-10(-592) gene polymorphism on 
cytokine expression in 116 CP patients and 173 control 
subjects. In CP, a significantly lower IL-10 mRNA 
expression was verified in both CA and AA genotypes 
when compared to CC genotype carriers. Also, in a 
study that investigated the possible association between 
IL-10(-592) and (-1082) SNPs and periodontal disease 
progression in a five year period was found that patients 
with IL-10 haplotypes experienced around 20% fewer 
PD ≥ 4mm compared to subjects with other genotypes.40 
Based on the present findings, IL-10(-592)AA genotypes 
did not seem to play a role in the periodontal therapy 
outcomes. Conversely, GCF IL-10 levels were higher in 
patients carrying IL-6 GG genotype compared to those 
of the IL-6 GC+CC genotype. This may be explained 
as a results of the production of anti-inflammatory 
cytokine IL-10 in order to reduce inflammation and 
reestablish homeostasis. 
Our study has some plausible limitations. The 
studied population was small, and therefore our 
findings needto be corroborated in larger samples 
Table 7. Differences of clinical parameters in generalized aggressive periodontitis patients (at baseline and 6-week) distributed by 
IL-6 and IL-10 genotypes.
Parameter
IL-6 (mean ± SD) IL-10 (mean ± SD)
GG GC+CC p-value AA AC+CC p-value
PI 1.19 ± 0.74 1.31 ± 0.64 0.58 1.08 ± 0.79 1.29 ± 0.67 0.40
GI 1.35 ± 0.55 1.63 ± 0.78 0.10 1.41 ± 0.66 1.48 ± 0.67 0.49
PD (mm) 2.09 ± 0.94 2.0 ± 1.06 0.63 1.91 ± 1.08 2.09 ± 0.96 0.80
CAL (mm) 1.64 ± 1.01 1.95 ± 1.13 0.32 2.0 ± 1.27 1.70 ± 1.0 0.57
PI: plaque index; GI: gingival index; PD: pocket depth; CAL: clinical attachment level.
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and should be tested ingroups of different ethnic 
origins. Also, other SNP of these genes and the effect 
of haplotype combinations have not been estimated. 
A precise statement about a possible association of 
a genetic locus with a disease can be only made if 
the full haplotype information has been assessed.38 
Conclusion
To the best of our knowledge, this is the first 
study evaluating outcomes of periodontal therapy 
on these gene polymorphisms in AgP patients in 
the Turkish population. IL-6(-174) and IL-10(-597) 
gene polymorphisms might be associated withAgP, 
but genotype distribution for the two cytokines 
did not influence periodontal treatment outcomes. 
However, GCF IL-10 levels were higher in the 
IL-6 GG genotype carriers at baseline and GCF 
IL-6 levels only decreased in patients with the 
IL-6 GC+CC and IL-10 AC+CC genotypes after 
periodontal treatment.
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